A materials scientist in Australia, by way of Iran, has recently had five papers retracted for duplicating his prior work, and the reader who brought the issue to publishers’ attention says it could affect some 100 articles.
Ali Nazari, now of Swinburne University of Technology in Australia, was at Islamic Azad University in Iran when he published the five papers in Energy and Buildings, an Elsevier title, in 2010 and 2011. The retractions came sometime after January of this year, when an anonymous reader contacted Elsevier about dozens of Nazari’s papers.
A gastroenterology journal has issued an extensive expression of concern about a 2013 paper by Yoshihiro Sato, a Japanese endocrinologist who has posthumously been climbing the Retraction Watch leaderboard. (He’s now ranked number three, ahead of Diederik Stapel.)
To call the statement an “expression of concern” is like calling Charles M. Schulz a talented cartoonist, or Escoffier a pretty good cook. Indeed, the journal expresses so much concern, about, well, so much, that we’re not sure what in the paper would be left unscathed.
Sato, formerly of Hirosaki University, currently has 77 retractions for a range of misconduct-related issues including likely data fabrication and duplication.
What has become clear in the intervening nine years is what a rich vein retractions are as stories of what happens when something goes wrong in science. And as we have done every year at this time, we’ll review what happened in the last 12 months.
Evidently meth is a gateway drug … for publishing misconduct.
Researchers in China have lost a 2019 paper on how LSD can damage eyesight because they’d lifted much of the paper from an article that had appeared the year before in a different journal — about methamphetamine.
The retracted article, “Long-term systemic treatment with lysergic acid diethylamide causes retinal damage in CD1 mice,” appeared in Human & Experimental Toxicology. According to the article:
A dermatology journal has retracted a 2017 article by a pair of researchers in Saudi Arabia after receiving a “serious complaint” about the integrity of the data. But the first author of the paper pushed back, saying the move was unjustified.
The article, “Successful use of combined corticosteroids and rituximab in a patient with refractory cutaneous polyarteritis nodosa,” was written by Ibrahim Al-Homood and Mohammad Aljahlan, rheumatologists at King Fahad Medical City in Riyadh and appeared in the Journal of Dermatology & Dermatologic Surgery. It described (with rather grisly pictures) the case of a 25-year-old man with severe leg ulcers that resolved after the described combination therapy.
But at the notice explains, the paper can’t be trusted: